These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 24166007)

  • 1. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
    Friedlander TW; Ngo VT; Dong H; Premasekharan G; Weinberg V; Doty S; Zhao Q; Gilbert EG; Ryan CJ; Chen WT; Paris PL
    Int J Cancer; 2014 May; 134(10):2284-93. PubMed ID: 24166007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.
    Premasekharan G; Gilbert E; Okimoto RA; Hamirani A; Lindquist KJ; Ngo VT; Roy R; Hough J; Edwards M; Paz R; Foye A; Sood R; Copren KA; Gubens M; Small EJ; Bivona TG; Collisson EA; Friedlander TW; Paris PL
    Cancer Lett; 2016 Sep; 380(1):144-52. PubMed ID: 27343980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
    Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
    Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
    Paller CJ; Piana D; Eshleman JR; Riel S; Denmeade SR; Isaacsson Velho P; Rowe SP; Pomper MG; Antonarakis ES; Luo J; Eisenberger MA
    Prostate; 2019 Oct; 79(14):1597-1603. PubMed ID: 31361358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
    Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
    Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
    Nagaya N; Nagata M; Lu Y; Kanayama M; Hou Q; Hotta ZU; China T; Kitamura K; Matsushita K; Isotani S; Muto S; Sakamoto Y; Horie S
    PLoS One; 2020; 15(1):e0226219. PubMed ID: 31986176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vita-Assay™ Method of Enrichment and Identification of Circulating Cancer Cells/Circulating Tumor Cells (CTCs).
    Tulley S; Zhao Q; Dong H; Pearl ML; Chen WT
    Methods Mol Biol; 2016; 1406():107-19. PubMed ID: 26820949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
    Cho H; Byun SS; Son NH; Chung JI; Seo WI; Lee CH; Morgan TM; Han KH; Chung JS
    Clin Cancer Res; 2024 May; 30(9):1788-1800. PubMed ID: 38587547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
    McDaniel AS; Ferraldeschi R; Krupa R; Landers M; Graf R; Louw J; Jendrisak A; Bales N; Marrinucci D; Zafeiriou Z; Flohr P; Sideris S; Crespo M; Figueiredo I; Mateo J; de Bono JS; Dittamore R; Tomlins SA; Attard G
    BJU Int; 2017 Nov; 120(5B):E30-E44. PubMed ID: 27539393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
    Scher HI; Armstrong AJ; Schonhoft JD; Gill A; Zhao JL; Barnett E; Carbone E; Lu J; Antonarakis ES; Luo J; Tagawa S; Dos Anjos CH; Yang Q; George D; Szmulewitz R; Danila DC; Wenstrup R; Gonen M; Halabi S
    Eur J Cancer; 2021 Jun; 150():83-94. PubMed ID: 33894633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
    Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
    Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
    Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
    Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer.
    Pearl ML; Zhao Q; Yang J; Dong H; Tulley S; Zhang Q; Golightly M; Zucker S; Chen WT
    Gynecol Oncol; 2014 Sep; 134(3):581-90. PubMed ID: 24972191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).
    Pearl ML; Dong H; Tulley S; Zhao Q; Golightly M; Zucker S; Chen WT
    Gynecol Oncol; 2015 May; 137(2):229-38. PubMed ID: 25769657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
    Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
    Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.
    Satelli A; Brownlee Z; Mitra A; Meng QH; Li S
    Clin Chem; 2015 Jan; 61(1):259-66. PubMed ID: 25336717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
    Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
    PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.
    Danila DC; Samoila A; Patel C; Schreiber N; Herkal A; Anand A; Bastos D; Heller G; Fleisher M; Scher HI
    Cancer J; 2016; 22(5):315-320. PubMed ID: 27749322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.